Setmelanotide
Also known as: Imcivree, RM-493, RHYTHM
Setmelanotide is an FDA-approved melanocortin-4 receptor (MC4R) agonist specifically designed to treat rare genetic forms of obesity. This synthetic peptide targets specific genetic mutations that disrupt normal appetite regulation and energy balance.
Setmelanotide is a 1001.15 Da research peptide. Setmelanotide is an FDA-approved melanocortin-4 receptor (MC4R) agonist specifically designed to treat rare genetic forms of obesity. This synthetic peptide targets specific genetic mutations that disrupt normal appetite regulation and energy balance.
Also called: Imcivree, RM-493, RHYTHM
1001.15
Molecular Weight
Daltons
3
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
1-3
Typical Dose
mg
Overview
Setmelanotide represents a breakthrough in treating monogenic obesity disorders caused by deficiencies in the leptin-melanocortin pathway. Unlike general weight loss medications, this MC4R agonist specifically addresses the underlying genetic mechanisms that prevent normal satiety signaling. The peptide binds to melanocortin-4 receptors in the hypothalamus, restoring appetite control and energy expenditure regulation that is disrupted in patients with POMC, PCSK1, or LEPR deficiency. Clinical trials demonstrate significant weight loss and improved metabolic parameters in patients with these rare genetic conditions. Research continues into its potential applications for other forms of hypothalamic obesity and metabolic disorders. The medication requires daily subcutaneous injection and careful monitoring due to its potent effects on melanocortin signaling pathways.
Key Takeaways: Setmelanotide
- Strongest evidence supports Setmelanotide for significant weight loss in genetic obesity and improved satiety signaling
- Research doses typically range from 1 to 3 mg via subcutaneous
- 3 benefits with strong evidence, 3 moderate, 0 preliminary
- Half-life: 1.5-2.5 hours
- 4 cited research studies in this guide
Mechanism of Action
Setmelanotide acts as a selective melanocortin-4 receptor agonist, binding to MC4R in the hypothalamic paraventricular nucleus. This activation restores downstream signaling through the cAMP pathway, promoting satiety and increasing energy expenditure. The peptide bypasses upstream defects in the leptin-melanocortin pathway, directly stimulating appetite suppression and metabolic rate enhancement. MC4R activation also influences glucose homeostasis and insulin sensitivity through central nervous system mechanisms.
Research Benefits
Setmelanotide at a Glance
Setmelanotide acts as a selective melanocortin-4 receptor agonist, binding to MC4R in the hypothalamic paraventricular nucleus.
Significant Weight Loss in Genetic Obesity
Strong EvidenceClinical trials show 25-32% reduction in body weight over 52 weeks in patients with POMC or PCSK1 deficiency. The weight loss occurs through restored appetite regulation rather than general metabolic suppression.
Improved Satiety Signaling
Strong EvidenceRestores normal hunger and fullness cues by activating MC4R receptors, allowing patients to recognize satiety signals that were previously absent due to genetic defects.
Reduced Hyperphagia
Strong EvidenceDramatically decreases compulsive eating behaviors characteristic of genetic obesity syndromes, allowing for normal meal patterns and portion control.
Enhanced Metabolic Rate
Moderate EvidenceIncreases energy expenditure through central melanocortin pathway activation, leading to higher resting metabolic rate and improved thermogenesis in genetically predisposed individuals.
Better Glucose Control
Moderate EvidenceImproves insulin sensitivity and glucose tolerance in patients with genetic obesity, potentially through both weight-dependent and weight-independent mechanisms involving MC4R signaling.
Cardiovascular Risk Improvement
Moderate EvidenceWeight loss achieved with setmelanotide leads to improvements in blood pressure, lipid profiles, and other cardiovascular risk markers in clinical studies.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Genetic obesity treatment | 1–3 mg | subcutaneous |
| Dose escalation protocol | 0.5–1 mg | subcutaneous |
Frequency
Once daily
Timing
Same time each day, preferably morning
Cycle Length
Continuous treatment as prescribed
Research Notes
- 1Start with lowest effective dose and titrate based on response
- 2Dose escalation should occur gradually over 2-4 week periods
- 3Maximum recommended dose is 3mg daily
- 4Injection site should be rotated to prevent lipodystrophy
- 5For research purposes only - not for human consumption
Reconstitution Guide
Standard Reconstitution
Vial Size
10 mg
Bacteriostatic Water
1 mL
Concentration
100 mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Setmelanotide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 1 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at 2-8°C (refrigerated). 28 days after reconstitution.
Storage Temperature
2-8°C (refrigerated)
Shelf Life
28 days after reconstitution
Important Notes
- •Use only bacteriostatic water for injection
- •Gently swirl to mix - do not shake vigorously
- •Solution should be clear and colorless
- •Discard if particulates or discoloration appear
- •Store in original packaging to protect from light
Setmelanotide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Setmelanotide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Injection site reactions (redness, swelling, pain)
- !Nausea and vomiting
- !Skin hyperpigmentation
- !Darkening of gums and oral mucosa
- !Spontaneous penile erections
- !Decreased appetite (intended effect)
- !Fatigue and lethargy
- !Headache
- !Abdominal pain
- !Depression or mood changes
Potential Interactions
- ⚡Other melanocortin receptor agonists (additive effects)
- ⚡Alpha-MSH analogs (potential receptor competition)
- ⚡Insulin and diabetes medications (may affect glucose control)
- ⚡Blood pressure medications (hypotensive effects possible)
- ⚡Antidepressants (mood-related interactions)
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome
Phase 3 trial showing significant weight loss and improved hunger scores in patients with Bardet-Biedl syndrome treated with setmelanotide for 52 weeks.
Setmelanotide treatment in patients with POMC deficiency obesity
Clinical trial demonstrating substantial weight loss and restoration of satiety in patients with pro-opiomelanocortin deficiency obesity.
Safety and efficacy of setmelanotide in individuals with LEPR deficiency
Study showing meaningful weight loss and improved metabolic parameters in patients with leptin receptor deficiency treated with setmelanotide.
Melanocortin-4 receptor agonism for hypothalamic obesity syndromes
Comprehensive review of MC4R agonist mechanisms and therapeutic applications in various forms of genetic and acquired hypothalamic obesity.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Setmelanotide activates melanocortin-4 receptors in the brain's appetite control center, bypassing genetic defects that prevent normal satiety signaling. This restores the ability to feel full after eating and increases metabolic rate.
Setmelanotide is approved for obesity caused by POMC, PCSK1, and LEPR gene deficiencies. Research continues for other genetic obesity syndromes including Bardet-Biedl syndrome and hypothalamic obesity.
Clinical trials show 25-32% body weight reduction over one year in patients with genetic obesity disorders. Individual results vary based on specific genetic condition and baseline characteristics.
The most frequent side effects include injection site reactions, nausea, skin darkening, and in males, spontaneous erections. These effects are generally dose-related and may improve over time.
Patients typically begin experiencing reduced hunger within the first few weeks of treatment. Significant weight loss usually becomes apparent after 2-3 months of consistent daily injections.
Setmelanotide is specifically designed for rare genetic forms of obesity and is not approved or recommended for common obesity. It targets specific genetic defects in appetite regulation pathways.
Unlike general weight loss medications that work through various mechanisms, setmelanotide specifically targets the melanocortin pathway to restore normal appetite regulation in patients with genetic defects.
The typical dose ranges from 1-3mg injected subcutaneously once daily. Treatment starts at lower doses and gradually increases based on response and tolerability over several weeks.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.